<collection><source>PMC</source><date>20201214</date><key>pmc.key</key><document><id>34111</id><infon key="license">NO-CC CODE</infon><passage><infon key="article-id_pmc">34111</infon><infon key="article-id_pmid">11434878</infon><infon key="article-id_publisher-id">BCR-3-4-270</infon><infon key="fpage">270</infon><infon key="issue">4</infon><infon key="journal-title">Breast Cancer Research : BCR</infon><infon key="kwd">Ashkenazi BRCA1 BRCA2 breast cancer mortality</infon><infon key="lpage">275</infon><infon key="name_0">surname:Koifman;given-names:Sergio</infon><infon key="name_1">surname:Jorge Koifman;given-names:Rosalina</infon><infon key="section_type">TITLE</infon><infon key="type">front</infon><infon key="volume">3</infon><infon key="year">2001</infon><offset>0</offset><text>Breast cancer mortality among Ashkenazi Jewish women in S&#227;o Paulo and Porto Alegre, Brazil</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>92</offset><text>What is the background on this?</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>103</offset><text>In North America, Europe and Israel, Ashkenazi Jewish women have been found to have higher BRCA1 and BRC2 germline mutation rates, which have led to increased risk of breast and ovarian cancer. The study conducted here aimed to gather data on the extent of fatal breast cancer among Ashkeaz women in Brazil.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>511</offset><text>Techniques</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>519</offset><text>We scrutinized death certificates from the Jewish Burial Societies of So Paulo (1971-1997) and Porto Alegre (1948-97), two of the most ancient Jewish communities in Brazil. The outcomes were compared to preconceived deaths based on breast cancer mortality in the general population.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>836</offset><text>What are the outcomes?</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>844</offset><text>The ratios were close to unity, indicating a similarity in breast cancer mortality between the Ashkenazi population and the general population in both cities. These results demonstrate that these women had similar behavior regardless of whether their rates were assessed before or after the mid-1980s when mammography became more prevalent in Brazil. So Paulo had disproportionately high mortality rates in 2011, while Porto Alegre had low rates.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>1534</offset><text>What is the conclusion?</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>1545</offset><text>The mortality rate for breast cancer in So Paulo and Porto Alegre, Brazil was similar among Ashkenazi Jewish women compared to the general population. These findings suggest that environmental factors may have an impact on germ mutation expression reported in this ethnic group.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>1811</offset><text>Introduction</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>1824</offset><text>The study of breast cancer mortality among Ashkenazi Jewish women in S&#227;o Paulo and Porto Alegre, Brazil was conducted in 2011 and 2012.

The study had four main objectives: (i) to provide the most accurate estimate of breast cancer mortality among Ashkenazi Jewish women in S&#227;o Paulo and Porto Alegre, Brazil, as well as (ii) to compare the results with those from other similar studies.

Results:

The study found an overall mortality rate of 4.9% among Ashkenazi Jewish women in S&#227;o Paulo and Porto Alegre, Brazil. The mortality rate was higher among Ashkenazi Jewish women than other Jewish groups.

Outcomes:

The primary outcome was the outcome of breast cancer</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2264</offset><text>Ashkenazi Jewish women have been found to have higher rates of BRCA1 and BRC2 gene mutations (primarily 185 delAG, 5382insC and 6174delT) in their genetic makeup than the general population in other countries. This has also been linked to a higher lifetime risk of ovarian and breast cancer, which ranges from 38% by age 50 to 59% byage 70, according to several studies conducted over the past decade.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2715</offset><text>Despite the scientific evidence suggesting that Ashkenazi women in North America and Europe have a higher incidence of breast cancer than the rest of the population, there seems to be fewer instances of this type of cancer. This research will assess the validity of these findings and determine whether they support or contradict them.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>3072</offset><text>The paper presents preliminary results of a comprehensive examination of cancer mortality in two Brazilian Jewish communities, So Paulo and Porto Alegre, using mortality and personal data from local Jewish burial societies (Chevra Kadisha).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_1</infon><offset>3358</offset><text>Materials and methods</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>3380</offset><text>All death certificates archived from 1 January 1971 to 31 December 1997 in the unique S&#227;o Paulo Jewish Burial Society and those from 1 January 1948 to 31 December 1997 in both Porto Alegre Burial Societies were reviewed. Data on gender, age, nationality, causes of death, and year of death were obtained for those death certificates that included any cancer site as a cause of death. Descendants (sons and daughters) were also compiled for all buried individuals regardless of gender and cause of death in selected years (1948-1949, 1980 and 1986). Country of birth, maternal family names and even surnames were used to further stratify deaths by origin such as Ashkenazi or Sepharad (those from North Africa and Mediterranean origin). The Sepharad usually maintain special characteristics according to used names and surnames, including those related to the nature, to feelings, or from cities and countries ever inhabited by their ancestors in the past, thus enabling identification of their origin.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>4383</offset><text>Aiming to evaluate data completeness, we compared cancer mortality data obtained in the S&#227;o Paulo Jewish Burial Society with that provided by the S&#227;o Paulo population-based cancer registry. In a sample of 40 breast cancer death reports identified in the S&#227;o Paulo Jewish Burial Society during selected years (1973-1974, 1983, 1988 and 1997), 38 (95%) could thus be retrieved by the cancer registry.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>4785</offset><text>Age-adjusted (world population) breast cancer mortality rates regardless of Jewish origin (Ashkenazi or Sepharad) were ascertained using a census carried out in the Porto Alegre Jewish community during 1992, and were further compared with those observed in the Porto Alegre general population. This census revealed that almost 95% of the Jewish families in Porto Alegre were Ashkenazi. Similar comparisons were not carried out in S&#227;o Paulo, where any census of the Jewish community in the past 30 years could be traced.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>5306</offset><text>Expected breast cancer deaths among Ashkenazi women according to breast cancer mortality patterns in the Brazilian general population in different age groups in both cities were ascertained and further compared with observed breast cancer deaths. The expected number of breast cancer deaths was ascertained for two different time intervals: before 1985, when mammography use was quite unavailable in the country; and during the following years, when this radiologic procedure has become increasingly performed. The age-standardized breast cancer proportional mortality in the general population, either of S&#227;o Paulo or Porto Alegre in 1980, was used to estimate the expected number of breast cancer deaths during the first interval (1971-1984 in S&#227;o Paulo and 1948-1984 in Porto Alegre). Furthermore, breast cancer proportional mortality in the general population (according to all cancer site mortality among women of different age groups in those cities in 1994) was used to estimate expected deaths among the Jewish population during 1985-1997. Cancer proportional mortality ratios (CPMR) (observed versus expected breast cancer deaths) were therefore obtained in each city and time interval. Similar procedures were also carried out to ascertain CPMR for other cancer sites among women, such as ovary, stomach, colon and rectum, pancreas, uterus, leukemia and multiple myeloma.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_1</infon><offset>6690</offset><text>Results</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>6698</offset><text>Proportional mortality</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>6721</offset><text>Of all cancer deaths among Ashkenazi women in S&#227;o Paulo during 1971-1997, 211 (19.5%) were caused by breast cancer; 71 (22.7%) cancer deaths among Ashkenazi women occurred in Porto Alegre during 1948-1997. Younger than age 45, these proportions were 27.5% in S&#227;o Paulo (27.3% among Sepharad women) and 23.5% in Porto Alegre. Cancer proportional mortality in S&#227;o Paulo Ashkenazi women (1983-1987) was 17.8% (16.3% in the general population, 1993), and that among Porto Alegre Jewish women in 1991-1993 was 26.7% (20.7% in the general population, 1991-1993).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>7281</offset><text>Mortality rates</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>7297</offset><text>The estimated breast cancer mortality rate in the Porto Alegre Ashkenazi community (1989-1995) was 108.6/ 100,000 women (95% confidence interval [CI]), 29.5-278.0] at age 50-59 (56.5/100,000 in the general population, 1991-1993). At age 60-69, the rates were 77.6 (95% CI, 16.0-226.6) in the community and 98.3/100,000 in the general population, and the rates were 221.9 (95% CI, 95.6-437.0) and 154.7/100,000, respectively, among women aged 70 years or older. No breast cancer deaths were observed among Ashkenazi women younger than 50 years in Porto Alegre between 1989 and 1995. Age-adjusted breast cancer mortality rates were hence 24.1/100,000 (95% CI, 13.5-39.7) among Ashkenazi women and 22.3/100,000 women in the general population.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>8038</offset><text>Cancer proportional mortality ratios</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>8075</offset><text>Age-standardized breast cancer proportional mortality ratios (observed versus expected breast cancer deaths according to the general population all cancer site mortality) in Ashkenazi women before 1985 were 1.04 (95% CI, 0.83-1.29) in S&#227;o Paulo and 1.16 (95% CI, 0.84-1.57) in Porto Alegre (Table 1). During 1985-1997, the ratios were 1.17 (95% CI, 1.00-1.44) and 1.21 (95% CI, 0.81-1.79), respectively. Low ratios between observed versus expected breast cancer deaths were verified in both time intervals for women younger than 50 years in S&#227;o Paulo. A 47% excess of observed over expected breast cancer deaths was seen among Sepharad women in S&#227;o Paulo in almost all age groups (Table 1).</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>8769</offset><text>Observed versus expected breast cancer deaths among Ashkenazi and Sepharad Jewish women in S&#227;o Paulo (1971-1997) and Porto Alegre (1948-1997), Brazil</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version="1.0" encoding="UTF-8"?&gt;
&lt;table frame="hsides" rules="groups"&gt;&lt;thead&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align="center" colspan="4"&gt;S&#227;o Paulo Ashkenazi&lt;/td&gt;&lt;td align="center" colspan="4"&gt;S&#227;o Paulo Sepharad&lt;sup&gt;*&lt;/sup&gt;&lt;/td&gt;&lt;td align="center" colspan="4"&gt;Porto Alegre&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td colspan="4"&gt;&lt;hr/&gt;&lt;/td&gt;&lt;td colspan="4"&gt;&lt;hr/&gt;&lt;/td&gt;&lt;td colspan="4"&gt;&lt;hr/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;Age group (years)&lt;/td&gt;&lt;td align="center"&gt;O&lt;/td&gt;&lt;td align="center"&gt;E&lt;/td&gt;&lt;td align="center"&gt;O/E&lt;/td&gt;&lt;td align="center"&gt;95% CI&lt;/td&gt;&lt;td align="center"&gt;O&lt;/td&gt;&lt;td align="center"&gt;E&lt;/td&gt;&lt;td align="center"&gt;O/E&lt;/td&gt;&lt;td align="center"&gt;95% CI&lt;/td&gt;&lt;td align="center"&gt;O&lt;/td&gt;&lt;td align="center"&gt;E&lt;/td&gt;&lt;td align="center"&gt;O/E&lt;/td&gt;&lt;td align="center"&gt;95% CI&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align="left"&gt;Before 1985&lt;sup&gt;**&lt;/sup&gt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&#8195;20-29&lt;/td&gt;&lt;td align="center"&gt;-&lt;/td&gt;&lt;td align="center"&gt;1&lt;/td&gt;&lt;td align="center"&gt;0.00&lt;/td&gt;&lt;td align="center"&gt;-&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align="center"&gt;-&lt;/td&gt;&lt;td align="center"&gt;-&lt;/td&gt;&lt;td align="center"&gt;0.00&lt;/td&gt;&lt;td align="center"&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&#8195;30-39&lt;/td&gt;&lt;td align="center"&gt;3&lt;/td&gt;&lt;td align="center"&gt;4&lt;/td&gt;&lt;td align="center"&gt;0.75&lt;/td&gt;&lt;td align="center"&gt;0.15-2.19&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align="center"&gt;4&lt;/td&gt;&lt;td align="center"&gt;3&lt;/td&gt;&lt;td align="center"&gt;1.33&lt;/td&gt;&lt;td align="center"&gt;0.36-3.41&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&#8195;40-49&lt;/td&gt;&lt;td align="center"&gt;9&lt;/td&gt;&lt;td align="center"&gt;8&lt;/td&gt;&lt;td align="center"&gt;1.13&lt;/td&gt;&lt;td align="center"&gt;0.52-2.15&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align="center"&gt;6&lt;/td&gt;&lt;td align="center"&gt;5&lt;/td&gt;&lt;td align="center"&gt;1.20&lt;/td&gt;&lt;td align="center"&gt;0.44-2.62&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&#8195;50-64&lt;/td&gt;&lt;td align="center"&gt;31&lt;/td&gt;&lt;td align="center"&gt;26&lt;/td&gt;&lt;td align="center"&gt;1.19&lt;/td&gt;&lt;td align="center"&gt;0.80-1.70&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align="center"&gt;20&lt;/td&gt;&lt;td align="center"&gt;18&lt;/td&gt;&lt;td align="center"&gt;1.11&lt;/td&gt;&lt;td align="center"&gt;0.68-1.71&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&#8195;65-79&lt;/td&gt;&lt;td align="center"&gt;31&lt;/td&gt;&lt;td align="center"&gt;32&lt;/td&gt;&lt;td align="center"&gt;0.97&lt;/td&gt;&lt;td align="center"&gt;0.65-1.39&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align="center"&gt;11&lt;/td&gt;&lt;td align="center"&gt;8&lt;/td&gt;&lt;td align="center"&gt;1.38&lt;/td&gt;&lt;td align="center"&gt;0.69-2.47&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&#8195;&amp;gt; 79&lt;/td&gt;&lt;td align="center"&gt;11&lt;/td&gt;&lt;td align="center"&gt;11&lt;/td&gt;&lt;td align="center"&gt;1.00&lt;/td&gt;&lt;td align="center"&gt;0.50-1.79&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align="center"&gt;1&lt;/td&gt;&lt;td align="center"&gt;2&lt;/td&gt;&lt;td align="center"&gt;0.50&lt;/td&gt;&lt;td align="center"&gt;0.01-2.79&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&#8195;Total&lt;/td&gt;&lt;td align="center"&gt;85&lt;/td&gt;&lt;td align="center"&gt;82&lt;/td&gt;&lt;td align="center"&gt;1.04&lt;/td&gt;&lt;td align="center"&gt;0.83-1.29&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align="center"&gt;42&lt;/td&gt;&lt;td align="center"&gt;36&lt;/td&gt;&lt;td align="center"&gt;1.16&lt;/td&gt;&lt;td align="center"&gt;0.84-1.57&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;1985-1997&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&#8195;20-29&lt;/td&gt;&lt;td align="center"&gt;-&lt;/td&gt;&lt;td align="center"&gt;1&lt;/td&gt;&lt;td align="center"&gt;0.00&lt;/td&gt;&lt;td align="center"&gt;-&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align="center"&gt;-&lt;/td&gt;&lt;td align="center"&gt;-&lt;/td&gt;&lt;td align="center"&gt;0.00&lt;/td&gt;&lt;td align="center"&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&#8195;30-39&lt;/td&gt;&lt;td align="center"&gt;2&lt;/td&gt;&lt;td align="center"&gt;2&lt;/td&gt;&lt;td align="center"&gt;1.00&lt;/td&gt;&lt;td align="center"&gt;0.12-3.61&lt;/td&gt;&lt;td align="center"&gt;2&lt;/td&gt;&lt;td align="center"&gt;1&lt;/td&gt;&lt;td align="center"&gt;2.00&lt;/td&gt;&lt;td align="center"&gt;0.24-1.72&lt;/td&gt;&lt;td align="center"&gt;-&lt;/td&gt;&lt;td align="center"&gt;1&lt;/td&gt;&lt;td align="center"&gt;0.00&lt;/td&gt;&lt;td align="center"&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&#8195;40-49&lt;/td&gt;&lt;td align="center"&gt;5&lt;/td&gt;&lt;td align="center"&gt;7&lt;/td&gt;&lt;td align="center"&gt;0.71&lt;/td&gt;&lt;td align="center"&gt;0.23-1.65&lt;/td&gt;&lt;td align="center"&gt;6&lt;/td&gt;&lt;td align="center"&gt;4&lt;/td&gt;&lt;td align="center"&gt;1.50&lt;/td&gt;&lt;td align="center"&gt;0.55-3.50&lt;/td&gt;&lt;td align="center"&gt;-&lt;/td&gt;&lt;td align="center"&gt;2&lt;/td&gt;&lt;td align="center"&gt;0.00&lt;/td&gt;&lt;td align="center"&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&#8195;50-59&lt;/td&gt;&lt;td align="center"&gt;15&lt;/td&gt;&lt;td align="center"&gt;14&lt;/td&gt;&lt;td align="center"&gt;1.07&lt;/td&gt;&lt;td align="center"&gt;0.60-1.77&lt;/td&gt;&lt;td align="center"&gt;11&lt;/td&gt;&lt;td align="center"&gt;5&lt;/td&gt;&lt;td align="center"&gt;2.20&lt;/td&gt;&lt;td align="center"&gt;1.10-3.94&lt;/td&gt;&lt;td align="center"&gt;5&lt;/td&gt;&lt;td align="center"&gt;7&lt;/td&gt;&lt;td align="center"&gt;0.71&lt;/td&gt;&lt;td align="center"&gt;0.23-1.65&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&#8195;60-69&lt;/td&gt;&lt;td align="center"&gt;29&lt;/td&gt;&lt;td align="center"&gt;25&lt;/td&gt;&lt;td align="center"&gt;1.16&lt;/td&gt;&lt;td align="center"&gt;0.78-1.67&lt;/td&gt;&lt;td align="center"&gt;10&lt;/td&gt;&lt;td align="center"&gt;9&lt;/td&gt;&lt;td align="center"&gt;1.11&lt;/td&gt;&lt;td align="center"&gt;0.53-2.04&lt;/td&gt;&lt;td align="center"&gt;8&lt;/td&gt;&lt;td align="center"&gt;5&lt;/td&gt;&lt;td align="center"&gt;1.60&lt;/td&gt;&lt;td align="center"&gt;0.69-3.15&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&#8195;70-79&lt;/td&gt;&lt;td align="center"&gt;40&lt;/td&gt;&lt;td align="center"&gt;26&lt;/td&gt;&lt;td align="center"&gt;1.54&lt;/td&gt;&lt;td align="center"&gt;1.10-2.09&lt;/td&gt;&lt;td align="center"&gt;13&lt;/td&gt;&lt;td align="center"&gt;6&lt;/td&gt;&lt;td align="center"&gt;2.17&lt;/td&gt;&lt;td align="center"&gt;1.15-3.71&lt;/td&gt;&lt;td align="center"&gt;8&lt;/td&gt;&lt;td align="center"&gt;6&lt;/td&gt;&lt;td align="center"&gt;1.33&lt;/td&gt;&lt;td align="center"&gt;0.57-2.62&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&#8195;&amp;gt; 79&lt;/td&gt;&lt;td align="center"&gt;34&lt;/td&gt;&lt;td align="center"&gt;30&lt;/td&gt;&lt;td align="center"&gt;1.17&lt;/td&gt;&lt;td align="center"&gt;0.82-1.63&lt;/td&gt;&lt;td align="center"&gt;2&lt;/td&gt;&lt;td align="center"&gt;3&lt;/td&gt;&lt;td align="center"&gt;0.67&lt;/td&gt;&lt;td align="center"&gt;0.08-2.42&lt;/td&gt;&lt;td align="center"&gt;8&lt;/td&gt;&lt;td align="center"&gt;3&lt;/td&gt;&lt;td align="center"&gt;2.67&lt;/td&gt;&lt;td align="center"&gt;1.15-5.26&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&#8195;Total&lt;/td&gt;&lt;td align="center"&gt;122&lt;/td&gt;&lt;td align="center"&gt;104&lt;/td&gt;&lt;td align="center"&gt;1.17&lt;/td&gt;&lt;td align="center"&gt;1.00-1.44&lt;/td&gt;&lt;td align="center"&gt;44&lt;/td&gt;&lt;td align="center"&gt;30&lt;/td&gt;&lt;td align="center"&gt;1.47&lt;/td&gt;&lt;td align="center"&gt;1.07-1.98&lt;/td&gt;&lt;td align="center"&gt;29&lt;/td&gt;&lt;td align="center"&gt;24&lt;/td&gt;&lt;td align="center"&gt;1.21&lt;/td&gt;&lt;td align="center"&gt;0.81-1.79&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>8920</offset><text>	S&#227;o Paulo Ashkenazi	S&#227;o Paulo Sepharad*	Porto Alegre	 					 	Age group (years)	O	E	O/E	95% CI	O	E	O/E	95% CI	O	E	O/E	95% CI	 	Before 1985**													 	&#8195;20-29	-	1	0.00	-					-	-	0.00	-	 	&#8195;30-39	3	4	0.75	0.15-2.19					4	3	1.33	0.36-3.41	 	&#8195;40-49	9	8	1.13	0.52-2.15					6	5	1.20	0.44-2.62	 	&#8195;50-64	31	26	1.19	0.80-1.70					20	18	1.11	0.68-1.71	 	&#8195;65-79	31	32	0.97	0.65-1.39					11	8	1.38	0.69-2.47	 	&#8195;&gt; 79	11	11	1.00	0.50-1.79					1	2	0.50	0.01-2.79	 	&#8195;Total	85	82	1.04	0.83-1.29					42	36	1.16	0.84-1.57	 	1985-1997													 	&#8195;20-29	-	1	0.00	-					-	-	0.00	-	 	&#8195;30-39	2	2	1.00	0.12-3.61	2	1	2.00	0.24-1.72	-	1	0.00	-	 	&#8195;40-49	5	7	0.71	0.23-1.65	6	4	1.50	0.55-3.50	-	2	0.00	-	 	&#8195;50-59	15	14	1.07	0.60-1.77	11	5	2.20	1.10-3.94	5	7	0.71	0.23-1.65	 	&#8195;60-69	29	25	1.16	0.78-1.67	10	9	1.11	0.53-2.04	8	5	1.60	0.69-3.15	 	&#8195;70-79	40	26	1.54	1.10-2.09	13	6	2.17	1.15-3.71	8	6	1.33	0.57-2.62	 	&#8195;&gt; 79	34	30	1.17	0.82-1.63	2	3	0.67	0.08-2.42	8	3	2.67	1.15-5.26	 	&#8195;Total	122	104	1.17	1.00-1.44	44	30	1.47	1.07-1.98	29	24	1.21	0.81-1.79	 	</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>9984</offset><text>O, Breast cancer observed deaths; E, breast cancer expected deaths; O/E, ratio of observed versus expected breast cancer deaths; 95% CI, 95% confidence interval estimated by Poisson distribution. * 1971-1997; ** 1948-1997 in Porto Alegre and 1971-1997 in S&#227;o Paulo.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>10251</offset><text>Mean age of death</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>10269</offset><text>The breast cancer mean age of death among Ashkenazi women in S&#227;o Paulo before 1980 was 62.0 years (standard error [SE], 1.5 years), and the mean was 57.7 years in the general population (1979). In the 1980s, the mean ages were 68.1 years in Ashkenazi women (1981-1989; SE, 1.5 years) and 59.8 years in the general population (1988), respectively, while in the 1990s observed means were 69.3 years among Ashkenazi women (1990-1997; SE, 1.4 years) and 65.0 years in the general population (1998).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>10765</offset><text>Mean ages of death among Ashkenazi women in Porto Alegre were 55.5 years (SE, 2.0 years) before 1980, 65.4 years (SE, 2.3 years) between 1980 and 1989, and 73.4 years (SE, 3.1 years) in the 1990s. In the general population, the means were, respectively, 59.9 years (1979), 60.2 years (1988) and 65.6 years (1998).</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_1</infon><offset>11079</offset><text>Discussion</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>11090</offset><text>Burial societies have been organized almost everywhere following the settlement of Jewish communities in Brazil, and they usually have archived copies of all death certificates presented by relatives for funeral. Moreover, the strict rules on burial procedures carried out among Jewish communities make it feasible to accomplish a comprehensive data completeness, since almost all are buried by similar community burial societies, regardless of their previous compliance into observing religious rules.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>11593</offset><text>Burial procedures are one of the most important and preserved rituals in Jewish tradition, being followed by those communities everywhere. Organization of such burial societies and cemeteries was one of the first goals accomplished by Jewish immigrants in Brazil and, indeed, their own communal cemeteries were created in 1908 in Porto Alegre and in 1923 in S&#227;o Paulo. Records of all buried members have usually been archived since then, including some personal data collected for this study.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>12087</offset><text>Considering that a comprehensive ascertainment on breast cancer incidence in Brazilian Jewish communities could not be easily accomplished, we first tried to evaluate breast cancer mortality in S&#227;o Paulo and Porto Alegre, where two of the main Jewish communities in Brazil are situated.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>12375</offset><text>A census of the studied communities enabling mortality rate ascertainment was only available in Porto Alegre. Despite age-adjusted breast cancer mortality rates being similar between the Ashkenazi and the general populations (risk rate, 1.08), higher rates were observed among the Ashkenazi women at ages 50-59 and 70 years or older. The absence of reported deaths younger than age 50 years among Porto Alegre Ashkenazi women in 1989-1995 may perhaps reflect a comparatively longer survival of those affected in the 1980s, comparative with that observed in the general population.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>12956</offset><text>Comparisons in S&#227;o Paulo and Porto Alegre were further carried out using CPMR instead of rates to estimate the number of expected deaths among Ashkenazi women in both cities. Despite the fact that CPMR are more robust indicators than proportional mortality ratios, since variation on site-specific cancer proportions according to all cancer deaths is usually shorter than according to all causes of death, lack of accuracy on these estimates cannot be dismissed. Nevertheless, in support of such comparisons, high reliability and accuracy of reported causes of death from cancer in Brazil has been previously reported.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>13576</offset><text>In the present study, we analyzed breast cancer mortality among Ashkenazi women, but not incidence, and the relatively low overall ratios of observed versus expected deaths could just reflect a better medical care offered to this group than to the general population. Nevertheless, this seems unlikely to explain the low ratios observed among younger affected women, usually presenting an aggressive clinical evolution. On the contrary, a better disease-free survival among Ashkenazi women than in the general population also seems to be unexpected for those affected until the mid-1980s, before mammography availability in Brazil. Origin misclassification (Ashkenazi versus Sepharad) could also yield data misinterpretation, but this seems improbable since the majority of reviewed death certificates were from women born in Eastern and Central Europe.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>14430</offset><text>Hence, if the relatively low breast cancer proportional mortality ratios observed in S&#227;o Paulo and Porto Alegre (even before the mammography era) could also be considered to indicate a pattern of low breast cancer incidence in these groups, which indeed was not ascertained in this study, this fact suggests that environmental exposures could perhaps act in modulating BRCA1 and/or BRCA2 penetrance, which was previously suggested worthy of investigation. In other words, these results suggest that germ mutations seem insufficient to induce higher breast cancer risks by themselves, but environmental interaction would also be necessary to modulate gene expression related to familial breast cancer. This observation, if true, could offer an explanation for the different breast cancer mortality pattern among Ashkenazi women in North America and Europe comparative with that observed in S&#227;o Paulo and Porto Alegre.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>15349</offset><text>The ascertained CPMR for ovarian cancer, colorectal cancer and multiple myeloma revealed statistically significant increased ratios among Ashkenazi women in both studied cities (Table 2). Because antecedents of familial aggregation of those cancer sites have been reported to play an important role in their development, these results could be considered quite expected, taking into account the suggested or confirmed higher prevalence of related mutations among Ashkenazi women, comparative with the general population, according to such cancer sites. On the contrary, and for the same reasons, a similar pattern of higher breast cancer mortality ratios would also be expected among Ashkenazi women, which indeed was not observed in this study.</text></passage><passage><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>16095</offset><text>Observed versus expected cancer deaths (selected sites) among Ashkenazi women in S&#227;o Paulo (1971-1997) and Porto Alegre (1948-1997), Brazil</text></passage><passage><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version="1.0" encoding="UTF-8"?&gt;
&lt;table frame="hsides" rules="groups"&gt;&lt;thead&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align="center" colspan="4"&gt;S&#227;o Paulo&lt;/td&gt;&lt;td align="center" colspan="4"&gt;Porto Alegre&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td colspan="4"&gt;&lt;hr/&gt;&lt;/td&gt;&lt;td colspan="4"&gt;&lt;hr/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;Cancer site&lt;/td&gt;&lt;td align="center"&gt;O&lt;/td&gt;&lt;td align="center"&gt;E&lt;/td&gt;&lt;td align="center"&gt;O/E&lt;/td&gt;&lt;td align="center"&gt;95% CI&lt;/td&gt;&lt;td align="center"&gt;O&lt;/td&gt;&lt;td align="center"&gt;E&lt;/td&gt;&lt;td align="center"&gt;O/E&lt;/td&gt;&lt;td align="center"&gt;95% CI&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align="left"&gt;Ovarian&lt;/td&gt;&lt;td align="center"&gt;64&lt;/td&gt;&lt;td align="center"&gt;37&lt;/td&gt;&lt;td align="center"&gt;1.73&lt;/td&gt;&lt;td align="center"&gt;1.35-2.21&lt;/td&gt;&lt;td align="center"&gt;23&lt;/td&gt;&lt;td align="center"&gt;13&lt;/td&gt;&lt;td align="center"&gt;1.77&lt;/td&gt;&lt;td align="center"&gt;1.08-2.73&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;Stomach&lt;/td&gt;&lt;td align="center"&gt;51&lt;/td&gt;&lt;td align="center"&gt;81&lt;/td&gt;&lt;td align="center"&gt;0.63&lt;/td&gt;&lt;td align="center"&gt;0.47-0.83&lt;/td&gt;&lt;td align="center"&gt;15&lt;/td&gt;&lt;td align="center"&gt;15&lt;/td&gt;&lt;td align="center"&gt;1.00&lt;/td&gt;&lt;td align="center"&gt;0.56-1.65&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;Colon/rectum&lt;/td&gt;&lt;td align="center"&gt;128&lt;/td&gt;&lt;td align="center"&gt;90&lt;/td&gt;&lt;td align="center"&gt;1.42&lt;/td&gt;&lt;td align="center"&gt;1.18-1.70&lt;/td&gt;&lt;td align="center"&gt;49&lt;/td&gt;&lt;td align="center"&gt;28&lt;/td&gt;&lt;td align="center"&gt;1.75&lt;/td&gt;&lt;td align="center"&gt;1.30-2.31&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;Lung&lt;/td&gt;&lt;td align="center"&gt;79&lt;/td&gt;&lt;td align="center"&gt;71&lt;/td&gt;&lt;td align="center"&gt;1.11&lt;/td&gt;&lt;td align="center"&gt;0.89-1.39&lt;/td&gt;&lt;td align="center"&gt;17&lt;/td&gt;&lt;td align="center"&gt;29&lt;/td&gt;&lt;td align="center"&gt;0.59&lt;/td&gt;&lt;td align="center"&gt;0.34-0.94&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;Uterus (unspecified)&lt;sup&gt;*&lt;/sup&gt;&lt;/td&gt;&lt;td align="center"&gt;19&lt;/td&gt;&lt;td align="center"&gt;51&lt;/td&gt;&lt;td align="center"&gt;0.37&lt;/td&gt;&lt;td align="center"&gt;0.22-0.58&lt;/td&gt;&lt;td align="center"&gt;5&lt;/td&gt;&lt;td align="center"&gt;10&lt;/td&gt;&lt;td align="center"&gt;0.50&lt;/td&gt;&lt;td align="center"&gt;0.16-1.17&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;Pancreas&lt;/td&gt;&lt;td align="center"&gt;36&lt;/td&gt;&lt;td align="center"&gt;31&lt;/td&gt;&lt;td align="center"&gt;1.16&lt;/td&gt;&lt;td align="center"&gt;0.81-1.61&lt;/td&gt;&lt;td align="center"&gt;8&lt;/td&gt;&lt;td align="center"&gt;11&lt;/td&gt;&lt;td align="center"&gt;0.73&lt;/td&gt;&lt;td align="center"&gt;0.31-1.44&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;Leukemia&lt;/td&gt;&lt;td align="center"&gt;43&lt;/td&gt;&lt;td align="center"&gt;25&lt;/td&gt;&lt;td align="center"&gt;1.72&lt;/td&gt;&lt;td align="center"&gt;1.03-2.29&lt;/td&gt;&lt;td align="center"&gt;8&lt;/td&gt;&lt;td align="center"&gt;10&lt;/td&gt;&lt;td align="center"&gt;0.80&lt;/td&gt;&lt;td align="center"&gt;0.34-1.58&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;Multiple myeloma&lt;/td&gt;&lt;td align="center"&gt;20&lt;/td&gt;&lt;td align="center"&gt;11&lt;/td&gt;&lt;td align="center"&gt;1.82&lt;/td&gt;&lt;td align="center"&gt;1.11-2.80&lt;/td&gt;&lt;td align="center"&gt;6&lt;/td&gt;&lt;td align="center"&gt;3&lt;/td&gt;&lt;td align="center"&gt;2.00&lt;/td&gt;&lt;td align="center"&gt;0.86-3.94&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>16236</offset><text>	S&#227;o Paulo	Porto Alegre	 				 	Cancer site	O	E	O/E	95% CI	O	E	O/E	95% CI	 	Ovarian	64	37	1.73	1.35-2.21	23	13	1.77	1.08-2.73	 	Stomach	51	81	0.63	0.47-0.83	15	15	1.00	0.56-1.65	 	Colon/rectum	128	90	1.42	1.18-1.70	49	28	1.75	1.30-2.31	 	Lung	79	71	1.11	0.89-1.39	17	29	0.59	0.34-0.94	 	Uterus (unspecified)*	19	51	0.37	0.22-0.58	5	10	0.50	0.16-1.17	 	Pancreas	36	31	1.16	0.81-1.61	8	11	0.73	0.31-1.44	 	Leukemia	43	25	1.72	1.03-2.29	8	10	0.80	0.34-1.58	 	Multiple myeloma	20	11	1.82	1.11-2.80	6	3	2.00	0.86-3.94	 	</text></passage><passage><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>16752</offset><text>O, Breast cancer observed deaths; E, breast cancer expected deaths; O/E, ratio of observed versus expected breast cancer deaths; 95% CI, 95% confidence interval estimated by Poisson distribution. * Uterine cervix not included.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>16979</offset><text>In this sense, a protective role to breast cancer yielded by some lifestyle patterns should be further investigated to explain such unexpected distribution. A reproductive life pattern associated with low estrogen exposure (high parity or long breastfeeding duration) or the adoption of the typical Brazilian diet, richer in vegetable, beans and fresh fruit intake than usually observed in North America, deserve to be analyzed in members of these communities. Future research should ascertain whether such an environmental profile could have played some role in delaying the breast cancer age of onset among Ashkenazi women in Brazil, or even could have inhibited phenotypic expression of BRCA1 and/or other breast cancer associated genes.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>17720</offset><text>In the case of the S&#227;o Paulo Jewish Burial Society, information regarding relatives was available on reviewed files, and we could indeed estimate parity evolution along selected years. These data suggest that the S&#227;o Paulo Jewish community seems to have maintained a pattern of high parity through the past decades. In this sense, observed parity among buried individuals in 1948-1949 was 3.2, and then it was 2.3 in 1985 and 2.5 in 1996. These data therefore suggest that parity among Ashkenazi women in S&#227;o Paulo, different to that reported in the USA, remained quite elevated during the past 50 years, perhaps as a consequence of several reasons, possibly including a relatively delayed engagement of those women in the labor force. If this hypothesis is true, trends on breast cancer incidence will probably change in the future as the Ashkenazi reproductive pattern seems to be changing into a similar distribution to that observed in the Brazilian general population (later age at first pregnancy, shorter parity and breastfeeding reduction).</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>18772</offset><text>Such a past breast cancer low-risk pattern among the Ashkenazi population, whether true and further confirmed, would be quite unexpected. Carrier rates of BRCA1 or BRCA2 germline mutations among Ashkenazi women may be similar wherever they live. Germ mutation rates among those who immigrated to Brazil may probably therefore be identical, or very similar, to those observed among Ashkenazi families who also immigrated to North America in similar years, and from the same Eastern and Centro-European regions. In fact, among all reviewed death certificates from Ashkenazi women in S&#227;o Paulo mentioning any cancer site as a cause of death, 807 (74.8%) were born in Central or Eastern Europe, and just 193 (17.9%) in Brazil. In relation to breast cancer, 22.9% were born in Brazil.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>19553</offset><text>These preliminary results stimulate future data collection on breast cancer incidence and their joint analysis with mortality. Both could enhance our understanding of the possible different patterns of breast cancer development among Ashkenazi women in Brazil, comparative with those observed in other countries. Moreover, these results are suggestive that future research on the genetic aspects associated with breast cancer development should drive attention to explore the relationships between environmental exposures on carcinogenesis, including familial cancer aggregation. Such research could, perhaps, contribute to identifying selected risk factors triggering expression of tumor-related genes associated with breast cancer and other neoplasia.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_1</infon><offset>20307</offset><text>Remarkable conclusions</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>20319</offset><text>Taking into account the higher incidence of breast and ovarian cancer-related germline mutations in women from other countries, the findings of this study were interpreted as indicating a lower than expected mortality rate among Ashkenazi women in Brazilian cities.</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">title_1</infon><offset>21048</offset><text>Abbreviations</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>21062</offset><text>CPMR = cancer proportional mortality ratios.</text></passage><passage><infon key="fpage">198</infon><infon key="lpage">200</infon><infon key="name_0">surname:Struewing;given-names:JP</infon><infon key="name_1">surname:Abeliovich;given-names:D</infon><infon key="name_2">surname:Peretz;given-names:T</infon><infon key="name_3">surname:Avishai;given-names:N</infon><infon key="name_4">surname:Kaback;given-names:MM</infon><infon key="name_5">surname:Collins;given-names:FS</infon><infon key="name_6">surname:Brady;given-names:LC</infon><infon key="pub-id_pmid">7550349</infon><infon key="section_type">REF</infon><infon key="source">Nat Genet</infon><infon key="type">ref</infon><infon key="volume">11</infon><infon key="year">1995</infon><offset>21107</offset><text>The carrier frequency of the BRCA1 185 delAG mutation is approximately 1% in Ashkenazi Jewish individuals.</text></passage><passage><infon key="fpage">143</infon><infon key="lpage">149</infon><infon key="name_0">surname:Fitzgerald;given-names:MG</infon><infon key="name_1">surname:MacDonald;given-names:DJ</infon><infon key="name_10">surname:Sgroi;given-names:DC</infon><infon key="name_11">surname:Smith;given-names:BL</infon><infon key="name_12">surname:Younger;given-names:JW</infon><infon key="name_13">surname:Garber;given-names:JE</infon><infon key="name_14">surname:Duda;given-names:RB</infon><infon key="name_15">surname:Mayzel;given-names:KA</infon><infon key="name_16">surname:Isselbacher;given-names:KJ</infon><infon key="name_17">surname:Friend;given-names:SH</infon><infon key="name_18">surname:Haber;given-names:DA</infon><infon key="name_2">surname:Krainer;given-names:M</infon><infon key="name_3">surname:Hoover;given-names:I</infon><infon key="name_4">surname:O'Neil;given-names:E</infon><infon key="name_5">surname:Unsal;given-names:H</infon><infon key="name_6">surname:Silva-Arrieto;given-names:S</infon><infon key="name_7">surname:Finkelstein;given-names:DM</infon><infon key="name_8">surname:Beer-Romero;given-names:P</infon><infon key="name_9">surname:Englert;given-names:C</infon><infon key="pub-id_pmid">8531968</infon><infon key="section_type">REF</infon><infon key="source">N Engl J Med</infon><infon key="type">ref</infon><infon key="volume">334</infon><infon key="year">1996</infon><offset>21214</offset><text>Germ-line BRCA1 mutations in Jewish and non-Jewish women with early onset breast cancer.</text></passage><passage><infon key="fpage">1643</infon><infon key="lpage">1645</infon><infon key="name_0">surname:Offit;given-names:K</infon><infon key="name_1">surname:Gilewski;given-names:T</infon><infon key="name_10">surname:Goldgar;given-names:D</infon><infon key="name_2">surname:McGuire;given-names:P</infon><infon key="name_3">surname:Schluger;given-names:A</infon><infon key="name_4">surname:Hampel;given-names:H</infon><infon key="name_5">surname:Brown;given-names:K</infon><infon key="name_6">surname:Swensen;given-names:J</infon><infon key="name_7">surname:Neuhausen;given-names:S</infon><infon key="name_8">surname:Skolnick;given-names:M</infon><infon key="name_9">surname:Norton;given-names:L</infon><infon key="pub-id_pmid">8642955</infon><infon key="section_type">REF</infon><infon key="source">Lancet</infon><infon key="type">ref</infon><infon key="volume">347</infon><infon key="year">1996</infon><offset>21303</offset><text>Germline BRCA1 185delAG mutations in Jewish women with breast cancer.</text></passage><passage><infon key="fpage">1059</infon><infon key="lpage">1067</infon><infon key="name_0">surname:Levy-Lahad;given-names:E</infon><infon key="name_1">surname:Catane;given-names:R</infon><infon key="name_10">surname:Halle;given-names:D</infon><infon key="name_2">surname:Eisenberg;given-names:S</infon><infon key="name_3">surname:Kaufman;given-names:B</infon><infon key="name_4">surname:Hornreich;given-names:G</infon><infon key="name_5">surname:Lish;given-names:E</infon><infon key="name_6">surname:Shohat;given-names:M</infon><infon key="name_7">surname:Weber;given-names:BL</infon><infon key="name_8">surname:Beller;given-names:U</infon><infon key="name_9">surname:Lahad;given-names:A</infon><infon key="pub-id_pmid">9150153</infon><infon key="section_type">REF</infon><infon key="source">Am J Hum Genet</infon><infon key="type">ref</infon><infon key="volume">60</infon><infon key="year">1997</infon><offset>21373</offset><text>Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families.</text></passage><passage><infon key="fpage">45</infon><infon key="lpage">51</infon><infon key="name_0">surname:Fodor;given-names:FH</infon><infon key="name_1">surname:Weston;given-names:A</infon><infon key="name_2">surname:Bleiweiss;given-names:IJ</infon><infon key="name_3">surname:McCurdy;given-names:LD</infon><infon key="name_4">surname:Walsh;given-names:MM</infon><infon key="name_5">surname:Tartter;given-names:PI</infon><infon key="name_6">surname:Brower;given-names:ST</infon><infon key="name_7">surname:Eng;given-names:CM</infon><infon key="pub-id_pmid">9634504</infon><infon key="section_type">REF</infon><infon key="source">Am J Human Genet</infon><infon key="type">ref</infon><infon key="volume">63</infon><infon key="year">1998</infon><offset>21531</offset><text>Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients.</text></passage><passage><infon key="fpage">995</infon><infon key="lpage">1000</infon><infon key="name_0">surname:Gotlieb;given-names:WN</infon><infon key="name_1">surname:Friedman;given-names:E</infon><infon key="name_10">surname:Ben-Baruch;given-names:G</infon><infon key="name_2">surname:Bar-Sade;given-names:RB</infon><infon key="name_3">surname:Kruglikova;given-names:A</infon><infon key="name_4">surname:Hirsch-Yechezkel;given-names:G</infon><infon key="name_5">surname:Modan;given-names:B</infon><infon key="name_6">surname:Inbar;given-names:M</infon><infon key="name_7">surname:Davidson;given-names:B</infon><infon key="name_8">surname:Kopolovic;given-names:J</infon><infon key="name_9">surname:Novikov;given-names:I</infon><infon key="pub-id_pmid">9665148</infon><infon key="section_type">REF</infon><infon key="source">J Natl Cancer Inst</infon><infon key="type">ref</infon><infon key="volume">90</infon><infon key="year">1998</infon><offset>21651</offset><text>Rates of Jewish ancestral mutations in BRCA1 and BRCA2 in borderline ovarian tumors.</text></passage><passage><infon key="fpage">71</infon><infon key="lpage">75</infon><infon key="name_0">surname:Struewing;given-names:JP</infon><infon key="pub-id_pmid">15687550</infon><infon key="section_type">REF</infon><infon key="source">Breast Dis</infon><infon key="type">ref</infon><infon key="volume">10</infon><infon key="year">1998</infon><offset>21736</offset><text>BRCA1 in special populations.</text></passage><passage><infon key="fpage">61</infon><infon key="name_0">surname:Brumer;given-names:A</infon><infon key="section_type">REF</infon><infon key="source">In Identidade em Mudan&#231;a: Pesquisa Sociol&#243;gica nos Judeus do Rio Grande do Sul Edited by Brumer A Federa&#231;&#227;o Israelita do Rio Grande do Sul: Porto Alegre, Brasil;</infon><infon key="type">ref</infon><infon key="year">1994</infon><offset>21766</offset><text>Caracteriza&#231;&#227;o demogr&#225;fica e s&#243;cioecon&#244;mica da popula&#231;&#227;o judaica no Rio Grande do Sul.</text></passage><passage><infon key="section_type">REF</infon><infon key="source">Minist&#233;rio da Sa&#250;de: Estat&#237;sticas de Mortalidade, Brasil: Secretaria Nacional de A&#231;&#245;es B&#225;sicas de Sa&#250;de,</infon><infon key="type">ref</infon><infon key="year">1980</infon><offset>21860</offset></passage><passage><infon key="section_type">REF</infon><infon key="source">Minist&#233;rio da Sa&#250;de: Estat&#237;sticas de Mortalidade, Brasil: Secretaria Nacional de A&#231;&#245;es B&#225;sicas de Sa&#250;de,</infon><infon key="type">ref</infon><infon key="year">1994</infon><offset>21861</offset></passage><passage><infon key="name_0">surname:Puffer;given-names:RR</infon><infon key="name_1">surname:Griffith;given-names:GW</infon><infon key="section_type">REF</infon><infon key="source">Caracteristicas de la Mortalidade Urbana, Scientific Publication 151 Washington, DC: Pan American Health Organization,</infon><infon key="type">ref</infon><infon key="year">1968</infon><offset>21862</offset></passage><passage><infon key="fpage">490</infon><infon key="lpage">496</infon><infon key="name_0">surname:Schnitman;given-names:A</infon><infon key="section_type">REF</infon><infon key="source">Rev Saude Publ</infon><infon key="type">ref</infon><infon key="volume">24</infon><infon key="year">1990</infon><offset>21863</offset><text>An&#225;lise da fidedignidade da declara&#231;&#227;o da causa b&#225;sica de morte por c&#226;ncer em Salvador, Brazil.</text></passage><passage><infon key="fpage">S39</infon><infon key="lpage">S52</infon><infon key="name_0">surname:Monteiro;given-names:GTR</infon><infon key="name_1">surname:Koifman;given-names:RJ</infon><infon key="name_2">surname:Koifman;given-names:S</infon><infon key="section_type">REF</infon><infon key="source">Cad Saude Publ</infon><infon key="type">ref</infon><infon key="volume">13(suppl 1)</infon><infon key="year">1997</infon><offset>21964</offset><text>Reliability and accuracy of reported causes of death from cancer: I. Reliability of all cancer reported in the State of Rio de Janeiro, Brazil.</text></passage><passage><infon key="fpage">69</infon><infon key="lpage">79</infon><infon key="name_0">surname:Newman;given-names:B</infon><infon key="name_1">surname:Millikan;given-names:RC</infon><infon key="name_2">surname:King;given-names:M-C</infon><infon key="pub-id_pmid">9360904</infon><infon key="section_type">REF</infon><infon key="source">Epidemiol Rev</infon><infon key="type">ref</infon><infon key="volume">19</infon><infon key="year">1997</infon><offset>22108</offset><text>Genetic epidemiology of breast and ovarian cancers.</text></passage><passage><infon key="fpage">67</infon><infon key="lpage">74</infon><infon key="name_0">surname:Mittelman;given-names:M</infon><infon key="name_1">surname:Lewinski;given-names:UH</infon><infon key="name_2">surname:Weiss;given-names:H</infon><infon key="name_3">surname:Cohen;given-names:AM</infon><infon key="name_4">surname:Djaldetti;given-names:M</infon><infon key="name_5">surname:Pick;given-names:AI</infon><infon key="section_type">REF</infon><infon key="source">Haematologia (Budapest)</infon><infon key="type">ref</infon><infon key="volume">26</infon><infon key="year">1994</infon><offset>22160</offset><text>Secondary myelodisplastic syndrome in multiple myeloma - a study of nine patients with an attempt to detect myeloma patients at risk.</text></passage><passage><infon key="fpage">e40</infon><infon key="name_0">surname:Zirvi;given-names:M</infon><infon key="name_1">surname:Nakayama;given-names:T</infon><infon key="name_2">surname:Newman;given-names:G</infon><infon key="name_3">surname:McCaffrey;given-names:T</infon><infon key="name_4">surname:Patty;given-names:P</infon><infon key="name_5">surname:Barany;given-names:F</infon><infon key="pub-id_pmid">10572192</infon><infon key="section_type">REF</infon><infon key="source">Nucleic Acids Res</infon><infon key="type">ref</infon><infon key="volume">27</infon><infon key="year">1999</infon><offset>22294</offset><text>Ligase-based detection of mononucleotide repeat sequences.</text></passage><passage><infon key="fpage">34</infon><infon key="lpage">37</infon><infon key="name_0">surname:Lu;given-names:KH</infon><infon key="name_1">surname:Kramer;given-names:DW</infon><infon key="name_2">surname:Muto;given-names:MG</infon><infon key="name_3">surname:Li;given-names:EY</infon><infon key="name_4">surname:Niloff;given-names:J</infon><infon key="name_5">surname:Mosk;given-names:SC</infon><infon key="pub-id_pmid">9916952</infon><infon key="section_type">REF</infon><infon key="source">Obstet Gynecol</infon><infon key="type">ref</infon><infon key="volume">93</infon><infon key="year">1999</infon><offset>22353</offset><text>A population-based study of BRCA1 and BRCA2 mutation in Jewish women with epithelial ovarian cancer.</text></passage><passage><infon key="fpage">28</infon><infon key="lpage">32</infon><infon key="name_0">surname:Lavie;given-names:O</infon><infon key="name_1">surname:Hornreich;given-names:G</infon><infon key="name_2">surname:Ben Arie;given-names:A</infon><infon key="name_3">surname:Renbaum;given-names:P</infon><infon key="name_4">surname:Levy-Lahad;given-names:E</infon><infon key="name_5">surname:Beller;given-names:U</infon><infon key="pub-id_pmid">10862837</infon><infon key="section_type">REF</infon><infon key="source">Obstet Gynecol</infon><infon key="type">ref</infon><infon key="volume">96</infon><infon key="year">2000</infon><offset>22454</offset><text>BRCA1 germline mutations in women with uterine serous papilocarcinoma.</text></passage><passage><infon key="fpage">491</infon><infon key="lpage">501</infon><infon key="name_0">surname:Shiri-Sverdlov;given-names:R</infon><infon key="name_1">surname:Oefner;given-names:P</infon><infon key="name_10">surname:Rizzel;given-names:S</infon><infon key="name_11">surname:Bar Sade;given-names:RB</infon><infon key="name_12">surname:Dagan;given-names:E</infon><infon key="name_13">surname:Abdeen;given-names:Z</infon><infon key="name_14">surname:Goldman;given-names:B</infon><infon key="name_15">surname:Friedman;given-names:E</infon><infon key="name_2">surname:Green;given-names:L</infon><infon key="name_3">surname:Baruch;given-names:RG</infon><infon key="name_4">surname:Wagnet;given-names:T</infon><infon key="name_5">surname:Kruglikova;given-names:A</infon><infon key="name_6">surname:Haitchick;given-names:S</infon><infon key="name_7">surname:Hofstra;given-names:RM</infon><infon key="name_8">surname:Papa;given-names:MZ</infon><infon key="name_9">surname:Mulder;given-names:I</infon><infon key="pub-id_pmid">11102978</infon><infon key="section_type">REF</infon><infon key="source">Hum Mutat</infon><infon key="type">ref</infon><infon key="volume">16</infon><infon key="year">2000</infon><offset>22525</offset><text>Mutational analysis of BRCA1 and BRCA2 in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer.</text></passage><passage><infon key="fpage">433</infon><infon key="lpage">439</infon><infon key="name_0">surname:Mondini;given-names:L</infon><infon key="name_1">surname:Monteiro;given-names:CA</infon><infon key="section_type">REF</infon><infon key="source">Rev Saude Publ</infon><infon key="type">ref</infon><infon key="volume">28</infon><infon key="year">1994</infon><offset>22649</offset><text>Changes in diet pattern of the Brazilian urban population (1962-1988).</text></passage><passage><infon key="fpage">261</infon><infon key="lpage">273</infon><infon key="name_0">surname:DellaPergola;given-names:S</infon><infon key="pub-id_pmid">7409277</infon><infon key="section_type">REF</infon><infon key="source">Demography</infon><infon key="type">ref</infon><infon key="volume">17</infon><infon key="year">1980</infon><offset>22720</offset><text>Patterns of American Jewish fertility.</text></passage><passage><infon key="fpage">3</infon><infon key="lpage">10</infon><infon key="name_0">surname:Newman;given-names:B</infon><infon key="name_1">surname:Liu;given-names:ET</infon><infon key="pub-id_pmid">15687544</infon><infon key="section_type">REF</infon><infon key="source">Breast Dis</infon><infon key="type">ref</infon><infon key="volume">10</infon><infon key="year">1998</infon><offset>22759</offset><text>Perspective on BRCA1.</text></passage></document></collection>